<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; Medtronic Incorporated</title>
	<atom:link href="http://www.stockbloghub.com/tag/medtronic-incorporated/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Wed, 23 May 2012 20:22:08 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(JNJ) Johnson &amp; Johnson&#8217;s Cypress Study Enrollment Begins</title>
		<link>http://www.stockbloghub.com/2009/09/01/jnj-johnson-johnsons-cypress-study-enrollment-begins/14085</link>
		<comments>http://www.stockbloghub.com/2009/09/01/jnj-johnson-johnsons-cypress-study-enrollment-begins/14085#comments</comments>
		<pubDate>Tue, 01 Sep 2009 21:53:23 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Incorporated]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=14085</guid>
		<description><![CDATA[Yesterday, Johnson &#38; Johnson (JNJ) announced the initiation of enrollment in the Cypress study (CYPherR for Evaluating Sustained Safety), which is designed to assess clinical outcomes in a wide range of patients suffering from coronary artery disease and taking dual anti-platelet therapy after receiving a Cypher Sirolimus-eluting Coronary Stent. The study, which will enroll approximately 2,000 patients, will be conducted at 200 centers throughout the U.S. Cypress will provide data for the clinical evaluation of the company’s new NEVO Sirolimus-eluting Coronary Stent in the NEVO III trial. NEVO III is a single-arm trial which is expected to serve as the pivotal trial for the pre-market application submission in the U.S. NEVO III will be conducted with approximately 1,200 patients in the United States and Canada. The Cypress trial is divided ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/09/01/jnj-johnson-johnsons-cypress-study-enrollment-begins/14085/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ABT) Abbott Unveils XIENCE PRIME</title>
		<link>http://www.stockbloghub.com/2009/09/01/abt-abbott-unveils-xience-prime/14102</link>
		<comments>http://www.stockbloghub.com/2009/09/01/abt-abbott-unveils-xience-prime/14102#comments</comments>
		<pubDate>Tue, 01 Sep 2009 21:18:31 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Incorporated]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=14102</guid>
		<description><![CDATA[Abbott Laboratories (ABT) yesterday announced the launch of its next-generation XIENCE PRIME Everolimus Eluting Coronary Stent System for the treatment of coronary artery disease (CAD). XIENCE PRIME is now available in Europe and other countries throughout Asia-Pacific and Latin America. XIENCE PRIME is the latest offering from Abbott&#8217;s robust vascular product division, which recorded strong growth in 2008 with sales coming in at $2.2 billion (up 35%). XIENCE PRIME received approval in the EU in June 2009. The widespread availability of XIENCE PRIME in Europe should help boost the company’s market share. Abbott is a major player in the drug-eluting stent  market with XIENCE V in its portfolio. XIENCE V is a drug coated stent that is used to treat CAD by propping open a narrowed or blocked artery and ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/09/01/abt-abbott-unveils-xience-prime/14102/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BSX) Boston Scientific is Ready For MADIT Results</title>
		<link>http://www.stockbloghub.com/2009/08/31/bsx-boston-scientific-is-ready-for-madit-results/13972</link>
		<comments>http://www.stockbloghub.com/2009/08/31/bsx-boston-scientific-is-ready-for-madit-results/13972#comments</comments>
		<pubDate>Mon, 31 Aug 2009 20:43:35 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Instruments & Supplies]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Incorporated]]></category>
		<category><![CDATA[St. Jude Medical Inc]]></category>
		<category><![CDATA[STJ]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=13972</guid>
		<description><![CDATA[Boston Scientific Corp. (BSX) is geared up for its landmark MADIT-CRT trial final results, which will be announced on Sept 1. The MADIT trial is evaluating the effectiveness of the company’s cardiac resynchronization therapy defibrillators (CRT-Ds), compared to the traditional implantable cardioverter defibrillators (ICDs). MADIT-CRT is the world’s largest randomized NYHA Class I/II CRT-D trial engulfing more than 1,800 asymptomatic or mildly symptomatic patients across 110 centers in 14 countries. Preliminary results from this trial were published on June 23, which indicated that the trial met its primary objectives. Results demonstrated a 29% reduction in death or heart failure in patients implanted with CRT-Ds as compared to ICDs. Positive final results will boost demand for Boston’s cardiac resynchronization therapy defibrillators, which will essentially drive the company’s top-line. Boston Scientific reported ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/08/31/bsx-boston-scientific-is-ready-for-madit-results/13972/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MDT) Medtronic Wins Settlement &#8211; Analyst Blog</title>
		<link>http://www.stockbloghub.com/2009/08/07/medtronic-wins-settlement-analyst-blog/12166</link>
		<comments>http://www.stockbloghub.com/2009/08/07/medtronic-wins-settlement-analyst-blog/12166#comments</comments>
		<pubDate>Fri, 07 Aug 2009 20:22:54 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Incorporated]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=12166</guid>
		<description><![CDATA[Medtronic Inc. (MDT) won $57 million in settlement from AGA Medical Corp. after the federal U.S. district court jury in San Francisco ruled in its favor. AGA had infringed upon two U.S. patents owned by Medtronic through the use and sale of Amplatzer Occluder and vascular plug products. Medtronic will also receive 11% in royalties from future sales of these products by AGA through 2018. The two patents in question are U.S. Patent Nos. 6,306,141 and 5,067,957, commonly known as the Jervis patents. These patents involve technologies that require the use of metal alloys to facilitate the working of doctors in different surgical operations. Medtronic has patents for these technologies. The new ruling is a shot in the arm for Medtronic. The additional revenue generated from this settlement will take ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/08/07/medtronic-wins-settlement-analyst-blog/12166/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

